Annual report pursuant to Section 13 and 15(d)

Statements of Operations

v3.22.4
Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating expenses:    
Research and development $ 5,651,041 $ 3,459,340
General and administrative 4,023,445 4,397,524
Total operating expenses 9,674,486 7,856,864
Loss from operations (9,674,486) (7,856,864)
Other income and expenses:    
Interest (income) expense, net (63,573) 45,613
Net loss (9,610,913) (7,902,477)
Deemed dividend upon the redemption of 5,221,156 shares of Series 1c preferred stock (see Note 6) 0 269,038
Deemed dividend upon the amendment of terms of the Series 1d convertible preferred stock (see Note 6) 0 2,293,199
Net loss attributable to common stockholders $ (9,610,913) $ (10,464,714)
Net loss per share of common stock, basic and diluted $ (0.87) $ (2.43)
Weighted-average basic and diluted common units/shares 11,050,662 4,302,232